Table 1: Survival distribution inputs.

PazopanibPlaceboReference

Weibull survival function parameters
 PFS (months)
  Lambda 0.12790.3714PALETTE
  Gamma 1.12521.0809PALETTE
 OS (months)
  Lambda 0.02820.0469PALETTE
  Gamma 1.23411.1027PALETTE
 PPS (months)
  Lambda 0.1040.118PALETTE
  Gamma 0.9020.898PALETTE
Probability of death without disease progression
(required for Markov cohort model)a
0.0530 PALETTE
HR for PFS for pazopanib versus comparator
 Ifosfamide0.91 (95% CI, 0.73–1.14) Sharma et al. 2013 [18]
van Oosterom et al. 2002 [43]
 Trabectedin0.90 (95% CI, 0.76–1.07)Sharma et al. 2013 [18]
Demetri et al. 2009 [44]
Garcia-Carbonero et al. 2005 [45]
le Cesne et al. 2005 [46]
Yovine et al. 2004 [47]
 Gemcitabine + docetaxel0.99 (95% CI, 0.70–1.40)Sharma et al. 2013 [18]
Hensley et al. 2008 [48]
Pautier et al. 2012 [33]

CI: confidence interval; HR: hazard ratio; OS: overall survival; PFS: progression-free survival; PPS: postprogression survival.
Same value was assumed for chemotherapies in indirect comparison.